Gilead Sciences Inc (GILD)
90.19
+0.43
(+0.48%)
USD |
NASDAQ |
Nov 22, 16:00
90.16
-0.03
(-0.03%)
Pre-Market: 20:00
Gilead Sciences Cash from Operations (Quarterly): 4.309B for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 4.309B |
| June 30, 2024 | 1.325B |
| March 31, 2024 | 2.219B |
| December 31, 2023 | 2.169B |
| September 30, 2023 | 1.755B |
| June 30, 2023 | 2.338B |
| March 31, 2023 | 1.744B |
| December 31, 2022 | 2.567B |
| September 30, 2022 | 2.863B |
| June 30, 2022 | 1.802B |
| March 31, 2022 | 1.84B |
| December 31, 2021 | 3.205B |
| September 30, 2021 | 3.253B |
| June 30, 2021 | 2.316B |
| March 31, 2021 | 2.61B |
| December 31, 2020 | 1.916B |
| September 30, 2020 | 2.25B |
| June 30, 2020 | 2.566B |
| March 31, 2020 | 1.436B |
| December 31, 2019 | 2.58B |
| September 30, 2019 | 2.645B |
| June 30, 2019 | 2.342B |
| March 31, 2019 | 1.577B |
| December 31, 2018 | 2.345B |
| September 30, 2018 | 2.212B |
| Date | Value |
|---|---|
| June 30, 2018 | 1.573B |
| March 31, 2018 | 2.27B |
| December 31, 2017 | 2.753B |
| September 30, 2017 | 2.694B |
| June 30, 2017 | 3.526B |
| March 31, 2017 | 2.925B |
| December 31, 2016 | 3.539B |
| September 30, 2016 | 4.393B |
| June 30, 2016 | 4.985B |
| March 31, 2016 | 4.13B |
| December 31, 2015 | 5.795B |
| September 30, 2015 | 4.096B |
| June 30, 2015 | 5.658B |
| March 31, 2015 | 5.701B |
| December 31, 2014 | 3.021B |
| September 30, 2014 | 4.044B |
| June 30, 2014 | 4.185B |
| March 31, 2014 | 1.568B |
| December 31, 2013 | 726.80M |
| September 30, 2013 | 753.10M |
| June 30, 2013 | 953.00M |
| March 31, 2013 | 672.10M |
| December 31, 2012 | 706.01M |
| September 30, 2012 | 745.37M |
| June 30, 2012 | 1.291B |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
1.325B
Minimum
Jun 2024
4.309B
Maximum
Sep 2024
2.353B
Average
2.283B
Median
Cash from Operations (Quarterly) Benchmarks
| Eli Lilly and Co | 3.712B |
| Merck & Co Inc | 9.291B |
| Pfizer Inc | 6.714B |
| Amgen Inc | 3.571B |
| Vertex Pharmaceuticals Inc | 1.370B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -710.00M |
| Cash from Financing (Quarterly) | -1.379B |
| Free Cash Flow | 9.431B |
| Free Cash Flow Per Share (Quarterly) | 3.324 |
| Free Cash Flow to Equity (Quarterly) | 4.269B |
| Free Cash Flow to Firm (Quarterly) | 4.412B |
| Free Cash Flow Yield | 8.35% |